CSs

ApprovedSmall molecule

Roche

CSs is one of 16 small molecule programs targeting Systemic Juvenile Idiopathic Arthritis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Juvenile Idiopathic ArthritisActive, not recruiting

Systemic Juvenile Idiopathic ArthritisApproved

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Systemic Juvenile Idiopathic Arthritis

#DrugCompanyPhaseTrials

Actemra

Roche

Phase 3

6 2

Ilaris

Novartis

Phase 3

4 3

Nsaids

Roche

Approved

1 4

Olumiant

Eli Lilly

Phase 3

1 5

Trexall

Alnylam Pharmaceuticals

Phase 3

1 6

Rinvoq

AbbVie

Phase 3

1 7

ACZ885

Novartis

Phase 3

2 8

Non-Steroidal Anti-Inflammatory Drugs (NSAID)

Roche

Phase 3

1 9

Mra(tocilizumab)

Roche

Phase 3

2 10

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Systemic Juvenile Idiopathic Arthritis1 trial

A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)

Completed· Roche logo

Roche·Phase 4·NCT03301883·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CSs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CSs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CSs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Roche

CSs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Systemic Juvenile Idiopathic Arthritis1 trial

References

Drug Info

Quick Facts

Related News